PUBLISHER: Grand View Research | PRODUCT CODE: 1511941
PUBLISHER: Grand View Research | PRODUCT CODE: 1511941
The global bioresorbable vascular scaffold market size is expected to reach USD 715.09 million by 2030, expanding at a CAGR of 8.7% from 2024 to 2030, based on a new Grand View Research, Inc. report. The market is experiencing significant growth driven by the increasing prevalence of cardiovascular diseases and the need for effective, minimally invasive treatments. According to the 2024 Heart Disease and Stroke Statistics Update Fact Sheet, cardiovascular disease (CVD) remains a significant public health concern in the U.S., with 931,578 deaths attributed to it as the underlying cause in 2021. The impact of heart disease and stroke is staggering, as they claimed more lives in 2021 than all forms of cancer and chronic lower respiratory disease combined.
The prevalence of CVD is alarmingly high, with 127.9 million US adults (48.6%) having some form of the disease between 2017 and 2020. The economic burden of CVD is also substantial, with direct and indirect costs totaling USD 422.3 billion between 2019 and 2020, including USD 254.3 billion in direct costs and USD 168.0 billion in lost productivity and mortality. These statistics underscore the urgent need for continued research, prevention, and treatment efforts to address the growing burden of cardiovascular disease in the U.S.
In addition to the increasing prevalence of CVD, technological advancements in the bioresorbable vascular scaffold (BVS) and a robust product pipeline are other factors expected to drive the growth of the market during the forecast period. For instance, in April 2024, the US Food and Drug Administration approved an everolimus-eluting bioresorbable scaffold (Esprit BTK) for patients with below-the-knee (BTK) infrapopliteal disease, according to an announcement from manufacturer Abbott. This approval highlights the ongoing development and innovation in the BVS market, providing new treatment options for patients with cardiovascular conditions.
Moreover, the evolution of next-generation bioresorbable vascular scaffolds (BRSs) with enhanced mechanical properties is a significant catalyst driving the global market's expansion. Previous versions of BRSs encountered challenges such as thicker struts and higher crossing profiles, limiting their widespread application. However, the latest BRSs utilize absorbable materials with superior mechanical attributes, enabling the production of thinner struts and reduced crossing profiles, improving deliverability, conformability, and flexibility for complex lesions and smaller vessels.
These advancements have resulted in improved clinical outcomes, including enhanced vessel healing, reduced restenosis rates, and decreased risks of adverse events like stent thrombosis, fostering increased adoption of BRSs worldwide. The growing preference for minimally invasive procedures, an aging population, and the escalating prevalence of cardiovascular diseases globally indicate a promising trajectory for the market on a global scale.